Here's a Way to Bet on High-Conviction Value Picks
Justin Kuepper
|
While there are many value-focused ETFs, active funds have the flexibility to pinpoint...
Gilead shares are pulling back significantly on today’s news. The only argument that Gilead could have is that today’s announcement limits patients’ options for treatment.
This is a very important event for biotech investors to be aware of since there could be similar moves in the near future, which can impact other biotech companies. If Express Scripts is saving by choosing the cheaper option, its peers including CVS Health (CVS), Aetna (AET) and UnitedHealth (UNH) could follow suit.
It is hard to say if investors should head for the exits on today’s biotech-related headlines. Considering the sector has had consecutive 50% gains, some profit-taking is likely in the cards.
Symbol | Mutual Fund | Stake |
---|---|---|
VTSMX | Vanguard Total Stock Mkt Idx | 1.37% |
FCNTX | Fidelity® Contrafund® | 1.34% |
VFINX | Vanguard 500 Index | 1.28% |
Shares of GILD are up 28% YTD.
Receive email updates about best performers, news, CE accredited webcasts and more.
Justin Kuepper
|
While there are many value-focused ETFs, active funds have the flexibility to pinpoint...
Aaron Levitt
|
All in all, bonds may not be serving all investors' needs in this...
Aaron Levitt
|
Despite all the backlash and recent laws in several states condemning ESG, the...
Mutual Fund Education
Justin Kuepper
|
Let's take a closer look at how ESG investments have outperformed during the...
Mutual Fund Education
Daniel Cross
|
While CITs and mutual funds share many similarities, there are some key differences...
Mutual Fund Education
Sam Bourgi
|
The phrase ‘bear market’ has been thrown around a lot lately, but it...
Gilead shares are pulling back significantly on today’s news. The only argument that Gilead could have is that today’s announcement limits patients’ options for treatment.
This is a very important event for biotech investors to be aware of since there could be similar moves in the near future, which can impact other biotech companies. If Express Scripts is saving by choosing the cheaper option, its peers including CVS Health (CVS), Aetna (AET) and UnitedHealth (UNH) could follow suit.
It is hard to say if investors should head for the exits on today’s biotech-related headlines. Considering the sector has had consecutive 50% gains, some profit-taking is likely in the cards.
Symbol | Mutual Fund | Stake |
---|---|---|
VTSMX | Vanguard Total Stock Mkt Idx | 1.37% |
FCNTX | Fidelity® Contrafund® | 1.34% |
VFINX | Vanguard 500 Index | 1.28% |
Shares of GILD are up 28% YTD.
Receive email updates about best performers, news, CE accredited webcasts and more.
Justin Kuepper
|
While there are many value-focused ETFs, active funds have the flexibility to pinpoint...
Aaron Levitt
|
All in all, bonds may not be serving all investors' needs in this...
Aaron Levitt
|
Despite all the backlash and recent laws in several states condemning ESG, the...
Mutual Fund Education
Justin Kuepper
|
Let's take a closer look at how ESG investments have outperformed during the...
Mutual Fund Education
Daniel Cross
|
While CITs and mutual funds share many similarities, there are some key differences...
Mutual Fund Education
Sam Bourgi
|
The phrase ‘bear market’ has been thrown around a lot lately, but it...